Evidence map›Paper›PMID 35579976›Full record

ArticleInternational journal of cancer2022

Circulating free testosterone and risk of aggressive prostate cancer: Prospective and Mendelian randomisation analyses in international consortia.

Eleanor L Watts, Aurora Perez-Cornago, Georgina K Fensom, Karl Smith-Byrne, Urwah Noor, Colm D Andrews, Marc J Gunter, Michael V Holmes, Richard M Martin, Konstantinos K Tsilidis and 56 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed, 4 pooled it
7.0field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 4 syntheses or guidelines pooled it, 50 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Review
  6. Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

66 authors at 20 institutions in 15 countries.

Eleanor L WattsCancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK.ORCID 0000-0001-9229-2589
Aurora Perez-CornagoCancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK.ORCID 0000-0002-5652-356X
Georgina K FensomCancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK.
Karl Smith-ByrneGenomic Epidemiology Branch, International Agency for Research on Cancer, Lyon, France.
Urwah NoorCancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK.
Colm D AndrewsCancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK.
Marc J GunterSection of Nutrition and Metabolism, International Agency for Research on Cancer, Lyon, France.
Michael V HolmesClinical Trial Service Unit and Epidemiological Studies Unit (CTSU), Nuffield Department of Population Health, University of Oxford, Oxford, UK.
Richard M MartinDepartment of Population Health Sciences, Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.
Konstantinos K TsilidisDepartment of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, UK.ORCID 0000-0002-8452-8472
Demetrius AlbanesDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Aurelio BarricarteNavarra Public Health Institute, Pamplona, Spain.
Bas Bueno-de-MesquitaCentre for Nutrition, Prevention and Health Services, National Institute for Public Health and the Environment (RIVM), The Netherlands.
Chu ChenProgram in Epidemiology, Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
Barbara A CohnChild Health and Development Studies, Public Health Institute, Berkeley, California, USA.
Niki L DimouSection of Nutrition and Metabolism, International Agency for Research on Cancer, Lyon, France.ORCID 0000-0003-1678-9328
Luigi FerrucciNational Institute on Aging, Baltimore, Maryland, USA.
Leon FlickerMedical School, University of Western Australia, Perth, Western Australia, Australia.
Neal D FreedmanDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Graham G GilesCancer Epidemiology Division, Cancer Council Victoria, Melbourne, Victoria, Australia.
Edward L GiovannucciDepartment of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.
Gary E GoodmanProgram in Epidemiology, Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
Christopher A HaimanCenter for Genetic Epidemiology, Department of Preventive Medicine, Keck School of Medicine, University of Southern California/Norris Comprehensive Cancer Center, Los Angeles, California, USA.
Graeme J HankeyMedical School, University of Western Australia, Perth, Western Australia, Australia.
Jiaqi HuangDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.ORCID 0000-0002-7808-9477
Wen-Yi HuangDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.ORCID 0000-0002-4440-3368
Lauren M HurwitzDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.ORCID 0000-0001-8932-5028
Rudolf KaaksDivision of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Paul KnektDepartment of Public Health and Welfare, National Institute for Health and Welfare, Helsinki, Finland.
Tatsuhiko KuboDepartment of Public Health and Health Policy, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
Hilde LangsethDepartment of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, UK.
Gail LaughlinHerbert Wertheim School of Public Health and Human Longevity Science, University of California San Diego, San Diego, California, USA.
Loic Le MarchandUniversity of Hawaii Cancer Center, Honolulu, Hawaii, USA.
Tapio LuostarinenFinnish Cancer Registry, Institute for Statistical and Epidemiological Cancer Research, Helsinki, Finland.ORCID 0000-0003-3231-8550
Robert J MacInnisCancer Epidemiology Division, Cancer Council Victoria, Melbourne, Victoria, Australia.
Hanna O MäenpääDepartment of Oncology, Helsinki University Central Hospital, Helsinki, Finland.
Satu MännistöDepartment of Public Health and Welfare, Finnish Institute for Health and Welfare, Helsinki, Finland.
E Jeffrey MetterDepartment of Neurology, The University of Tennessee Health Science Center, College of Medicine, Memphis, Tennessee, USA.
Kazuya MikamiDepartmemt of Urology, Japanese Red Cross Kyoto Daiichi Hospital, Kyoto, Japan.
Lorelei A MucciDepartment of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.
Anja W OlsenDepartment of Public Health, Aarhus University, Aarhus, Denmark.
Kotaro OzasaDepartmemt of Epidemiology, Radiation Effects Research Foundation, Hiroshima, Japan.
Domenico PalliCancer Risk Factors and Life-Style Epidemiology Unit, Institute for Cancer Research, Prevention and Clinical Network - ISPRO, Florence, Italy.ORCID 0000-0002-5558-2437
Kathryn L PenneyDepartment of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.
Elizabeth A PlatzDepartment of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.ORCID 0000-0003-3676-8954
Harri RissanenDepartment of Public Health and Welfare, National Institute for Health and Welfare, Helsinki, Finland.
Norie SawadaEpidemiology and Prevention Group, Center for Public Health Sciences, National Cancer Center, Tokyo, Japan.ORCID 0000-0002-9936-1476
Jeannette M SchenkCancer Prevention Program, Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
Pär StattinDepartment of Surgical Sciences, Uppsala University, Uppsala, Sweden.
Akiko TamakoshiHokkaido University Faculty of Medicine, Sapporo, Japan.
Elin ThysellDepartment of Medical Biosciences, Umeå University, Umeå, Sweden.
Chiaojung Jillian TsaiDepartment of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Shoichiro TsuganeEpidemiology and Prevention Group, Center for Public Health Sciences, National Cancer Center, Tokyo, Japan.
Lars VattenDepartment of Public Health and Nursing, Faculty of Medicine, Norwegian University of Science and Technology, Trondheim, Norway.
Elisabete WeiderpassDirector Office, International Agency for Research on Cancer, World Health Organization, Lyon, France.ORCID 0000-0003-2237-0128
Stephanie J WeinsteinDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Lynne R WilkensUniversity of Hawaii Cancer Center, Honolulu, Hawaii, USA.
Bu B YeapMedical School, University of Western Australia, Perth, Western Australia, Australia.
PRACTICAL Consortium
CRUK
BPC3
CAPS
PEGASUS
Naomi E AllenClinical Trial Service Unit and Epidemiological Studies Unit (CTSU), Nuffield Department of Population Health, University of Oxford, Oxford, UK.
Timothy J KeyCancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK.
Ruth C TravisCancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK.
University of Oxford · GBNational Institutes of Health · USCentre international de recherche sur le cancer · FRFinnish Institute for Health and Welfare · FIThe University of Western Australia · AUBrigham and Women's Hospital · USFred Hutch Cancer Center · USThe University of Melbourne · AUUniversity of Hawaiʻi at Mānoa · USAarhus University · DKCancer Registry of Norway · NOFinnish Cancer Registry · FIGerman Cancer Research Center · DEHarvard University · USHelsinki University Hospital · FIHiroshima University · JPHokkaido University · JPInstituto de Salud Pública de Navarra · ESJohns Hopkins University · USKyoto first Red Cross hospital · JP

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
SWOG NCORP Research BaseUG1CA189974 · NCI · THE HOPE FOUNDATION · PI CHARLES D. BLANKE, DAWN HERSHMAN · 2014 to 2026
$80.6M
University of Hawaii Cancer Center CCSGP30CA071789 · NCI · UNIVERSITY OF HAWAII AT MANOA · PI GERTRAUD MASKARINEC · 1996 to 2026
$56.2M
Understanding Population Differences in Cancer: The MEC StudyU01CA164973 · NCI · UNIVERSITY OF HAWAII AT MANOA · PI HAIMAN, CHRISTOPHER ALAN, LE MARCHAND, LOIC · 2015 to 2025
$37.4M
PLCO Trial Etiologic and Early Marker StudyZIACP010152 · NCI · DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS · PI MOORE, STEVEN · 2009 to 2025
$29.9M
Southern Community Cohort StudyU01CA202979 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI BLOT, WILLIAM J., SHRUBSOLE, MARTHA J. · 2016 to 2025
$22.0M
Cancer Epidemiology Cohort in Male Health ProfessionalsU01CA167552 · NCI · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI Lorelei Mucci, Walter C. Willett · 2017 to 2026
$17.0M
THE CAROTENE AND RETINOL EFFICACY TRIAL (CARET)U01CA063673 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI GOODMAN, GARY E · 1994 to 2006
$13.0M
PCPT and SELECT Cohorts: Core Infrastructure Support for Cancer ResearchU01CA182883 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI TANGEN, CATHERINE M., THOMPSON, IAN M. · 2019 to 2023
$5.4M
CLUE STUDIES--EVALUATING BIOMARKERS OF CARCINOGENESISU01CA086308 · NCI · JOHNS HOPKINS UNIVERSITY · PI HELZLSOUER, KATHY J · 2000 to 2004
$4.2M
Infrastructure Support and Pilot Tissue Collection for the CARET BiorepositoryU01CA167462 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI NEUHOUSER, MARIAN L · 2018 to 2022
$2.9M
INFRASRUCTURE SUPPORT AND DATA ENHANCEMENTS FOR THE CARET BIOREPOSITORYUM1CA167462 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI GOODMAN, GARY E · 2013 to 2017
$2.8M
Cancer Research UK 29017Cancer Research UK 29019Cancer Research UK A19170Cancer Research UK A29019Intramural NIH HHS Z99 CA999999Medical Research Council MC_PC_17228Medical Research Council MC_QA137853NCI NIH HHS P30 CA008748NCI NIH HHS P30 CA071789NCI NIH HHS U01 CA063673NCI NIH HHS U01 CA086308NCI NIH HHS U01 CA164973NCI NIH HHS U01 CA167462NCI NIH HHS U01 CA167552NCI NIH HHS U01 CA182883NCI NIH HHS UG1 CA189974NCI NIH HHS UM1 CA167462NIA NIH HHS U01 AG018033World Health Organization 001
6 · The paper itself

Abstract

Previous studies had limited power to assess the associations of testosterone with aggressive disease as a primary endpoint. Further, the association of genetically predicted testosterone with aggressive disease is not known. We investigated the associations of calculated free and measured total testosterone and sex hormone-binding globulin (SHBG) with aggressive, overall and early-onset prostate cancer. In blood-based analyses, odds ratios (OR) and 95% confidence intervals (CI) for prostate cancer were estimated using conditional logistic regression from prospective analysis of biomarker concentrations in the Endogenous Hormones, Nutritional Biomarkers and Prostate Cancer Collaborative Group (up to 25 studies, 14 944 cases and 36 752 controls, including 1870 aggressive prostate cancers). In Mendelian randomisation (MR) analyses, using instruments identified using UK Biobank (up to 194 453 men) and outcome data from PRACTICAL (up to 79 148 cases and 61 106 controls, including 15 167 aggressive cancers), ORs were estimated using the inverse-variance weighted method. Free testosterone was associated with aggressive disease in MR analyses (OR per 1 SD = 1.23, 95% CI = 1.08-1.40). In blood-based analyses there was no association with aggressive disease overall, but there was heterogeneity by age at blood collection (OR for men aged <60 years 1.14, CI = 1.02-1.28; P

Indexed as

Prostatic NeoplasmsSex Hormone-Binding GlobulinBiomarkersHumansMaleMendelian Randomization AnalysisProstateRisk FactorsTestosteroneBiomarkersSex Hormone-Binding GlobulinTestosteroneaggressive prostate cancerMendelian randomisationprostate cancerSHBGtestosterone

Identifiers

PMID35579976
PMCPMC7613289
OpenAlexW4280491083

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.